Related Experiment Video
Updated: Mar 8, 2026

A Murine Model of Hemodialysis Access-Related Hand Dysfunction
Published on: May 31, 2022
Differential response of bone and kidney to ACEI in db/db mice: A potential effect of captopril on accelerating bone
Yan Zhang1, Xiao-Li Li2, Nan-Nan Sha1
1Spine Disease Research Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
Abstract:
The components of renin-angiotensin system (RAS) are expressed in the kidney and bone. Kidney disease and bone injury are common complications associated with diabetes. This study aimed to investigate the effects of an angiotensin-converting enzyme inhibitor, captopril, on the kidney and bone of db/db mice. The db/db mice were orally administered by gavage with captopril for 8weeks with db/+ mice as the non-diabetic control. Serum and urine biochemistries were determined by standard colorimetric methods or ELISA. Histological measurements were performed on the kidney by periodic acid-schiff staining and on the tibial proximal metaphysis by safranin O and masson-trichrome staining. Trabecular bone mass and bone quality were analyzed by microcomputed tomography. Quantitative polymerase chain reaction and immunoblotting were applied for molecular analysis on mRNA and protein expression. Captopril significantly improved albuminuria and glomerulosclerosis in db/db mice, and these effects might be attributed to the down-regulation of angiotensin II expression and the expression of its down-stream profibrotic factors in the kidney, like connective tissue growth factor and vascular endothelial growth factor. Urinary excretion of calcium and phosphorus markedly increased in db/db mice in response to captopril. Treatment with captopril induced a decrease in bone mineral density and deterioration of trabecular bone at proximal metaphysis of tibia in db/db mice, as shown in the histological and reconstructed 3-dimensional images. Even though captopril effectively reversed the diabetes-induced changes in calcium-binding protein 28-k and vitamin D receptor expression in the kidney as well as the expression of RAS components and bradykinin receptor-2 in bone tissue, treatment with captopril increased the osteoclast-covered bone surface, reduced the osteoblast-covered bone surface, down-regulated the expression of type 1 collagen and transcription factor runt-related transcription factor 2 (markers for osteoblastic functions), and up-regulated the expression of carbonic anhydrase II (marker for bone resorption). Captopril exerted therapeutic effects on renal injuries associated with type 2 diabetes but worsened the deteriorations of trabecular bone in db/db mice; the latter of which was at least in part due to the stimulation of osteoclastogenesis and the suppression of osteogenesis by captopril.
Insights
Captopril, an angiotensin-converting enzyme inhibitor, improved kidney function in diabetic mice but worsened bone density. This highlights a potential trade-off in treating diabetic complications with this drug.
Area of Science:
- Endocrinology and Metabolism
- Nephrology
- Orthopedics
Background:
- Diabetes mellitus is frequently associated with kidney disease and bone complications.
- The renin-angiotensin system (RAS) plays a role in both kidney and bone physiology.
- Angiotensin-converting enzyme (ACE) inhibitors are used to manage hypertension and diabetic nephropathy.
Purpose of the Study:
- To investigate the effects of captopril on kidney and bone in a mouse model of type 2 diabetes (db/db mice).
- To elucidate the molecular mechanisms underlying captopril's actions on renal and skeletal tissues.
Main Methods:
- db/db mice and non-diabetic db/+ mice were treated with captopril or vehicle for 8 weeks.
- Kidney and bone tissues were analyzed using biochemical assays, histology, microcomputed tomography, qPCR, and immunoblotting.
- Parameters assessed included renal function markers, bone mineral density, bone microarchitecture, and gene/protein expression related to RAS, fibrosis, and bone metabolism.
Main Results:
- Captopril significantly ameliorated albuminuria and glomerulosclerosis in db/db mice, linked to reduced angiotensin II and profibrotic factor expression in the kidney.
- However, captopril treatment led to increased urinary calcium and phosphorus excretion, decreased bone mineral density, and deteriorated tibial trabecular bone structure.
- Molecular analysis revealed captopril's impact on bone metabolism, including increased osteoclast activity and decreased osteoblast function markers.
Conclusions:
- Captopril demonstrates therapeutic benefits for diabetic kidney injury by modulating the intrarenal RAS.
- Conversely, captopril treatment negatively impacts bone health in diabetic mice, potentially by promoting osteoclastogenesis and inhibiting osteogenesis.
- These findings suggest a complex interplay between RAS inhibition, renal protection, and bone metabolism in diabetes.
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers

